Virax Biolabs Group Ltd balance sheet VRAX
As of Mar 31, 2025, Virax Biolabs Group Ltd had total assets of $6.4 million and total liabilities of $964,750. Total assets were up 17.2% from a year earlier. Stockholders' equity was $5.5 million. It held $4.2 million in cash and investments against $344,536 of total debt, net cash of $3.9 million. The current ratio, current assets divided by current liabilities, was 7.27.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2025
Mar 31, 2025
|
FY 2024
Mar 31, 2024
|
FY 2023
Mar 31, 2023
|
FY 2022
Mar 31, 2022
|
|---|---|---|---|---|
| Assets | ||||
| Cash |
4
+17.8%
|
4
-61.6%
|
9
+42888.3%
|
0
|
| Cash and investments |
4
+17.8%
|
4
-61.6%
|
9
+42888.3%
|
0
|
| Inventory |
0
+56.8%
|
0
+188.2%
|
—
|
0
|
| Total current assets |
5
+11.7%
|
4
-54.5%
|
10
+19679.9%
|
0
|
| Property and equipment, net |
1
+36.6%
|
1
|
—
|
—
|
| Total assets |
6
+17.2%
|
5
-44.1%
|
10
+20046.2%
|
0
|
| Liabilities and equity | ||||
| Total current liabilities |
1
+298.7%
|
0
-81.4%
|
1
-27.1%
|
1
|
| Total liabilities |
1
+179.5%
|
0
-62.0%
|
1
-27.1%
|
1
|
| Stockholders' equity |
5
+6.3%
|
5
-42.3%
|
9
+844.0%
|
-1
|
| Debt | ||||
| Lease liabilities |
0
+53.6%
|
0
|
—
|
—
|
| Total debt |
0
-51.6%
|
0
|
—
|
—
|
| Net cash |
4
+35.0%
|
3
|
—
|
—
|
| Ratios | ||||
| Current ratio |
7.27x
|
25.94x
|
10.61x
|
0.04x
|
| Debt to equity |
0.06x
|
0.04x
|
—
|
—
|
| Return on equity |
-111.08%
|
-131.14%
|
-61.30%
|
—
|
| Return on assets |
-94.40%
|
-122.89%
|
-55.62%
|
-3,592.72%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.